Document Detail


Reperfusion of chronic tissue ischemia: nitrite and dipyridamole regulation of innate immune responses.
MedLine Citation:
PMID:  20955430     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Chronic and intermittent ischemic vascular disorders represent a burgeoning clinical challenge. Previous studies have focused on the idea that therapeutic angiogenesis strategies could alleviate tissue ischemia; however, it is now appreciated that vascular disease is not simply limited to vascular wall cells but also influenced by simultaneously occurring inflammatory responses. Our laboratory has discovered that pharmacological treatment of permanent tissue ischemia with dipyridamole significantly augments ischemic tissue reperfusion, angiogenesis, and arteriogenesis over time. We have found that the beneficial effects of dipyridamole therapy are due to its ability to increase tissue nitric oxide bioavailability that corrects tissue redox imbalance. Importantly, we have also discovered that dipyridamole treatment invoking nitric oxide (NO) production significantly downregulates various innate immune response genes during chronic ischemic tissue injury. These findings demonstrate that dipyridamole-induced production of nitrite/NO significantly decreases inflammatory responses while increasing vascular growth in ischemic tissues.
Authors:
Christopher B Pattillo; Kai Fang; Justin Terracciano; Christopher G Kevil
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1207     ISSN:  1749-6632     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-19     Completed Date:  2010-11-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  83-8     Citation Subset:  IM    
Copyright Information:
© 2010 New York Academy of Sciences.
Affiliation:
Department of Pathology, LSU Health Sciences Center-Shreveport, Shreveport, Louisiana, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Dipyridamole / pharmacology*
Down-Regulation / drug effects
Humans
Immunity, Innate / drug effects*,  genetics
Inflammation / prevention & control
Ischemia / drug therapy*,  immunology*,  metabolism
Neovascularization, Physiologic / drug effects
Nitric Oxide / metabolism
Nitrites / pharmacology*
Reperfusion / methods*
Grant Support
ID/Acronym/Agency:
HL 080482/HL/NHLBI NIH HHS; HL 094021/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Nitrites; 10102-43-9/Nitric Oxide; 58-32-2/Dipyridamole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Protecting against ischemia-reperfusion injury: antiplatelet drugs, statins, and their potential int...
Next Document:  Effect of intravenous administration of dipyridamole in a rat model of chronic cerebral ischemia.